1.3
Klinische proeven: Overzicht
Klinische ontwikkeling richt zich op hoe het geneesmiddel met het menselijk lichaam zal interageren en omvat vier belangrijke fasen van klinische proe…
Clinical trials are research studies that assess a candidate drug's pharmacological properties in humans. These trials are conducted in multiple phases.
In phase I, five to ten candidate drugs from successful preclinical studies are tested on a small group of either healthy individuals or patients to evaluate various effects, such as potential toxicity, side effects, pharmacokinetics, and pharmacodynamics.
Successful candidates from phase I are tested in phase II on a hundred to three hundred patients to monitor drug efficacy and dosage regulation.
Candidates that pass phase II screening are tested in phase III for their safety and efficacy. Phase III trials are double-blind studies conducted on thousands of patients across many centers.
After a successful phase III trial, a New Drug Application is submitted to the FDA for marketing approval.
Once the drug is FDA-approved, the manufacturer produces and places the drug on the market.
Postmarketing surveillance, or phase IV, is done to study the drug's long-term or rare adverse effects.
View the full transcript and gain access to JoVE Core videos
Q1: What happens in phase I of a clinical trial?
Phase I tests five to ten candidate drugs on a small group of healthy individuals or patients to evaluate toxicity, side effects, pharmacokinetics, and pharmacodynamics. This initial phase determines whether the drug is safe enough to proceed to larger patient populations and establishes baseline tolerability and safety data for advancement.
Q2: How do phase II and phase III clinical trials differ?
Phase II expands testing to 100-300 patients to monitor drug efficacy and dosage regulation. Phase III involves double-blind, randomized trials with thousands of patients across multiple centers to comprehensively compare the new drug against existing alternatives or placebos, making it more costly and time-consuming than phase II.
Q3: What is the purpose of phase IV trials?
Phase IV, or postmarketing surveillance, monitors long-term and rare adverse effects in large patient populations after FDA approval. This ongoing phase ensures drug safety continues to be tracked throughout its use in the general population and identifies effects that may not appear in earlier trial phases.
Q4: What happens after a successful phase III trial?
After phase III success, a New Drug Application is submitted to the FDA with a detailed dossier of preclinical and clinical data. The FDA reviews the submission, and approval can take a year or longer, with approximately two-thirds of submissions receiving marketing approval for commercial distribution.
Q5: How long does the entire drug development process take?
The complete drug development process, including clinical trials, spans 7 to 12 years. This extended timeline reflects the rigorous testing required across preclinical development overview phases, multiple clinical trial phases, and regulatory review before a drug reaches the market for patient use.
Q6: What standards must clinical trials follow?
Clinical trials must adhere to Good Clinical Practice guidelines, ensuring meticulous patient group selection, data collection, statistical analysis, and documentation. Phase III trials increasingly incorporate pharmacoeconomic analysis to assess both clinical and economic benefits of new drugs before regulatory submission and approval.
Q7: What determines whether a drug candidate advances from phase I testing?
Successful candidates from phase I demonstrate acceptable safety profiles and provide data on pharmacokinetics and pharmacodynamics. Only drugs showing sufficient tolerability and lack of prohibitive toxicity advance to phase II testing in larger patient groups to evaluate therapeutic efficacy and optimal dosage.